Led regulatory strategy development and implementation efforts culminating in the first US and EU marketing approvals for small pharma company.
Advanced from Harvard Medical School post-doctoral fellowship to lead multiple preclinical & clinical virology studies.
Grew small biotech start-up with upside to 150-person, publicly-traded company with approved, marketed product.
Secured $150M financing and prepared Peloton Therapeutics for IPO — laying groundwork for Merck & Co. acquisition.
Led deal-critical Hepatitis C project at Arrow Therapeutics prior to acquisition by AstraZeneca.